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ABSTRACT
Background and Objectives: Vascular smooth muscle cell (VSMC) proliferation is responsible for the restenosis of previ-
ously inserted coronary stents. Angiotensin II (Ang II) is known to regulate VSMC proliferation. LKB1, a serine/threonine ki-
nase, interacts with the p53 pathway and acts as a tumor suppressor. Materials and Methods: We assessed the association of 
Ang II and the expression of LKB1 in primary cultured murine VSMCs and neointima of the Sprague Dawley rat carotid ar-
tery injury model. We created carotid balloon injuries and harvested the injured carotid arteries 14 days after the procedure. 
Results: Ang II increased LKB1 expression in a time-dependent manner and peaked at an Ang II concentration of 10
-7 mole/L 
in VSMCs. In the animal experiment, neointima was markedly increased after balloon injury compared to the control group. 
Immunohistochemical studies showed that LKB1 expression increased according to neointima thickness. Ang II augmented 
LKB1 expression after the injury. Western blot analysis of LKB1 with carotid artery lysate revealed the same pattern as LKB1 
immunohistochemistry. Increased LKB1 expression started at 5 days after the balloon injury, and peaked at 14 days after the 
injury. Although LKB1 expression was increased after the injury, LKB1 kinase activity was not increased. Ang II or balloon-
injury increased the expression of LKB1 although the LKB1 activity was reduced. Conclusion: Ang II increased LKB1 ex-
pression in VSMCs and neointima. These findings were not kinase dependant. (Korean Circ J 2010;40:552-557)
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Introduction
Coronary artery disease is one of the leading causes of death 
and disability. Percutaneous coronary intervention (PCI) is 
one of the most widely used therapeutic procedures in the tr-
eatment of obstructive coronary artery disease. Although 
drug-eluting stents are commonly used to decrease in-stent 
restenosis (ISR), the ISR after PCI remains a major limitation 
of the treatment. The proliferative action of vascular smooth 
muscle cells (VSMCs) has been found to play an important role 
in restenosis through neointima formation after PCI.
1-4)
Peutz-Jeghers syndrome (PJS) is a rare autosomal domi-
nantly inherited disorder in which patients develop gastroin-
testinal hamartomatous polyposis, and mucocutaneous pig-
mentation on skin and oral mucosa. PJS is also associated with 
a 15-fold increased risk of developing cancer and a functional 
loss of serine/threonine kinase LKB1. Inactivation of germ line 
mutations in the LKB1 gene underlies the majority of PJS cas-
es.
5) LKB1 is therefore believed to function as a tumor sup-
pressor.
6)7) LKB1/STK11 encodes a serine/threonine protein ki-
nase with widespread expression during murine embryonic de-
velopment. LKB1-deficient mice undergo embryonic lethality 
during the midgestational period, showing severe vascular ab-
normalities due to defective vasculogenesis associated with a Jin-Ok Jeong, et al.   553
tissue-specific deregulation of vascular endothelial growth fac-
tor.
7) Overexpression of wild-type LKB1 in vitro induces a G1 
cell cycle arrest and suppresses growth in tumor cell lines. 
Overexpressed LKB1 increases expression of several p21 (CDK 
inhibitor), p53 responsive genes.
8-11) This tumor suppressor pro-
tein may have an important role in atherosclerosis, especially 
in restenosis. Cellular stress (such as deoxyribonucleic acid da-
mage, hypoxia, and oxidized lipoprotein) activates p53. LKB1 
interacts with the p53 pathway, suppresses cellular prolifera-
tion, and has a proapoptotic effect.
8)11-13) These findings sup-
port the hypothesis that LKB1 protein kinase functions reg-
ulate cellular proliferation as a tumor suppressor. 
We examined whether LKB1 regulates VSMC proliferation 
and neointima formation in rat carotid artery injury models.
Materials and Methods
Cell culture
VSMCs were prepared from the aorta of 4-6 week old Spra-
gue Dawley (SD) rats (Charles River Laboratories, Japan). 
Cells were grown in DMEM/F12 containing 10% (v/v) fetal bo-
vine serum (FBS), penicillin (100 units/mL), and streptomycin 
(100 mg/mL) (Gibco/BRL). Cells were passaged at 90% con-
fluence and utilized between passages 4 and 10. Cells grown 
confluently in growth medium were kept for 48 hours in DM-
EM/F12 medium containing 5×10
-7 M insulin (Sigma), 5 
mg/mL transferrin (Sigma), and 0.2 mM ascorbic acid (Sigma). 
Quiescence was induced by incubation for 72 hours in low-
mitogen (0.5% FBS) medium.
Rat carotid artery injury model
Procedures involving animals were in accordance with the 
Guide for Experimental Animal Research from the Laborato-
ry for Experimental Animal Research, and the Clinical Rese-
arch Institute, Chungnam National University Hospital. The 
model of balloon injury was based on that described by Clo-
wes et al.
1)14-17) Male SD rats (mean weight 350 g) aged 8 to 10 
weeks were used. Briefly, under xylazine (5 mg/kg intraperi-
toneally; Bayer, Korea) and ketamine hydrochloride (50 mg/kg 
intraperitoneally; Yuhan Corp, Korea) anesthesia, the right ex-
ternal carotid arteries were exposed, and the common carot-
id arteries were denuded of endothelium by the intraluminal 
passage of a 2-French embolectomy arterial catheter (Baxter 
Healthcare Corp), which was passed to the proximal common 
carotid artery and withdrawn. This procedure was repeated 
five times. In the angiotensin II (Ang II) group, Ang II (0.5 mg/ 
kg/day), purchased from Sigma Aldich, was infused via mi-
niosmotic pumps (ALZET, CA, USA), which were implanted 
immediately after the injury, with Ang II released over two weeks. 
Histological analysis and morphometry
At the time of euthanasia, a midline abdominal incision 
was performed, and the distal abdominal aorta was exposed. 
Perfusion fixation used phosphate-buffered saline and 4% 
paraformaldehyde over five minutes at 120 mmHg. The in-
jured segment of the right common carotid artery was dis-
sected from the surrounding tissue, fixed in 10% formalin, 
and embedded in paraffin. Several 4 μm sections were cut 
from each specimen. Sections were stained with hematoxylin-
eosin (H&E) for conventional light microscopic analysis. Mor-
phometric analyses of the arterial segments were performed 
by an observer blinded to the study groups using computerized 
image processing and an analysis program (ImageJ, Version 
1.41 for Windows, NIH). 
Immunohistochemistry was performed with monoclonal 
antibodies to LKB1 (Cell Signaling, USA) using an EnVision 
kit (DAKO, Carpinteria, CA, USA) and hematoxylin stain. Dia-
minobenzidine was used to visualize the sites of primary an-
tibody binding to the antigen. Expression of LKB1 was graded 
according to the following scale by two investigators blinded 
to the experimental conditions: negative (0), mild staining (1), 
moderate staining (2), and intense staining (3).
LKB1 western blot
Western blot assays were performed as previously describ-
ed
18) with antibodies against LKB1 (Cell signaling technology, 
MA, USA). Briefly, VSMCs were growth arrested for 24 hours 
and treated with various cytokines for 48 hours. Cells were 
harvested in sodium dodecyl sulfate sample buffer. Western 
blot analysis was performed with an anti-LKB1 antibody. 
After vascular injury, the carotid arterial tissue samples 
were homogenized with radio immunoprecipitation assay 
(RIPA) buffer. The carotid artery lysates containing an equal 
amount of protein from each condition were analyzed by wes-
tern blotting for LKB1. All determinations were performed 
in triplicate.
LKB1 kinase assay
Kinase assays were performed as previously described.
19) 
After vascular injury, the carotid arterial tissue samples were 
homogenized with 400 μL of RIPA buffer. The carotid artery 
lysates containing an equal amount of protein (100 μg) were 
overnight incubated with anti-LKB1 antibody (Santa Cruz) 
and centrifuged using protein A-G agarose. LKB1 Kinsae 
buffer, LKB1 substrate 1 μL, Mg++/ATP 2 μL, and [γ-32P]
ATP 1 μL were added. After incubation for 30 minutes at 30°C 
with constant agitation, the reaction was stopped by adding 5 
μL of 3% phosphoric acid. A 20 μL aliquot was spotted onto 
the center of a P81 paper square (Upstate Biotechnology), 
allowed to dry, then washed three times with 0.75% phos-
phoric acid and aceton. After transferring the paper square to 
a sealable plastic bag and adding 3 mL of scintillation cocktail, 
radioactivity was measured in a scintillation counter (TRI-
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Statistical analysis
All data were expressed as mean±standard error of mean. 
Statistical analysis was performed using commercial statistical 
analysis software. Continuous variables were compared using 
Mann-Whitney U-test and Student t-tests. Categorical vari-
ables were compared using χ2-test. A value of p<0.05 was con-
sidered to be statistically significant.
Results
Angiotensin II increased LKB1 expression 
in vascular smooth muscle cells
We tested various cytokines such as Ang II, tumor necrosis 
factor alpha, interferon gamma, tumor growth factor beta and 
platelet derived growth factor (data not shown). We found 
increased expression of LKB1 under Ang II stimulated con-
ditions. Treatment with Ang II led to increased serine/threo-
nine kinase LKB1 in rat VSMCs (Fig. 1A). Ang II increased 
the LKB1 expression showed a bell shaped curve. The LKB1 
expression peaked at an Ang II concentration of 10
-7 mole/L 
and then decreased at an Ang II concentration of 10
-5 mole/L 
(Fig. 1B). Induction of LKB1 peaked after 48 hours in the pres-
ence of Ang II (100 nM) for the indicated times (Fig. 1C). 
LKB1 expression increased in neointima 
of balloon-injured carotid arteries
H-E staining showed neointima formation 2 weeks after 
the carotid artery balloon injury. The neointima was formed 
in the balloon injury group and the balloon injury with Ang 
II infusion group (Fig. 2A, B and C). There were no signifi-
cant differences of neointima formation between the injury 
and the injury with Ang II infusion group. Immunohisto-
chemistry showed increased LKB1 expression after the carot-
id artery balloon injury compared to the control group (Fig. 
2D and E). Ang II augmented the increased expression of LKB1 
(Fig. 2F). 
Western blot analysis of LKB1 with carotid artery lysate 
revealed the same pattern as LKB1 immunohistochemistry 
(Fig. 2I). Western blot of LKB1 expression increased in the 
carotid artery balloon injury model compared to the control 
group. Ang II augmented the increased expression of LKB1. 
Serial LKB1 staining showed LKB1 expression increased 5 
days after the balloon injury and peaked 14 days after the 
injury according to neointima formation (Fig. 3).
The amount of LKB1 protein was not correlated 
with LKB1 kinase activity in balloon-injured 
carotid arteries
We originally hypothesized that increased LKB1 might 
inhibit cell proliferation of VSMCs in vitro and also neointi-
ma formation in vivo. However, according to our data, Ang II-
induced LKB1 actually led to increased proliferation of VS-
MCs. To elucidate this discrepancy between the hypothesis 
and the data, we measured LKB1 kinase activity in balloon-
injured carotid arteries. Balloon injury increased the expres-
sion of LKB1 although LKB1 activity was reduced. This means 
that the amount of LKB1 protein was not correlated with 
LKB1 activity (Fig. 4).
Discussion
In this study, we demonstrated the increased expression of 
LKB1 in the VSMCs by Ang II and neointima of injured rat ca-
rotid artery. Ang II stimulates VSMC proliferation. LKB1 ex-
pression was increased at Ang II concentrations of 10
-7 mole/L 
and peaked at 48 hours in VSMCs. Post-injury neointima for-
mation was increased in the injury group and the Ang II in-
fusion group compared with the control group. Also, LKB1 ex-
pression was significantly increased in neointima. However, 
increased LKB1 expression was not correlated with LKB1 ac-
tivity in the balloon-injured carotid artery. These findings sup-
port the hypothesis that the serine/threonine kinase LKB1, a 
tumor suppressor, increases after vascular injury and is in-
volved in the regulation of VSMC proliferation and apoptosis. 
LKB1 is an upstream kinase of AMP-activated protein ki-
nase (AMPK), a cellular energy sensor. It is known that AM-
PK inhibits Ang II-stimulated VSMC proliferation.
20) Although 
LKB1 is one of the important modulators of AMPK, Ang II did 
not induce AMPK phosphorylation (data not shown). VSMCs 
and rabbit aorta expressed the upstream AMPK kinase LKB1 
Fig. 1. A: VSMCs were growth arrested for 24 hours and treated with 
Ang II for 48 hours. Cells were harvested in sodium dodecyl sulfate 
sample buffer. Western blot analysis was performed with anti-LKB1 
antibody. The results are representative of 3 experiments. Ang II in-
creases serine/threonine kinase LKB1 in rat VSMCs. B: induction of 
LKB1 by Ang II in VSMCs. Quiescent VSMCs were maintained un-
der control conditions in the presence of the indicated concentration 
of Ang II for 48 hours. Induction of LKB1 by Ang II peaked at an Ang 
II concentration of 10
-7 mole/L. C: time response of LKB1 by Ang II. 
Quiescent VSMCs were maintained in the presence of Ang II (100 nM) 
for the indicated times. Induction of LKB1 peaked at 48 hours. TNF-α: 
tumor necrosis factor alpha, Ang II: angiotensin II, VSMCs: vascu-
lar smooth muscle cells.
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protein, and rottlerin-induced AMPK activation was decre-
ased in VSMCs by overexpression of dominant negative LKB1, 
suggesting that LKB1 is involved in the upstream regulation 
of AMPK stimulated by rottlerin.
21) These data therefore imply 
that LKB1 mediates rottlerin-induced activation of AMPK 
in vascular cells and tissues. 
Although LKB1 and AMPK have become attractive thera-
peutic targets for vascular diseases, the functions of LKB1 and 
AMPK activation are still not fully understood. AMPK activa-
tion suppresses protein synthesis and prevents cardiac myo-
cyte hypertrophy by regulation of the eEF2 kinase/eEF2 axis 
and/or TSC2-mTOR-P70S6 pathways.
22-24) LKB1 has been re-
ported to cause G1 growth arrest in cultured cells via induction 
of p21WAF1/CIP1
11) and stimulation of Brg1 ATPase.
25) LKB1 
kinase activity is required for p21WAF1/CIP1 induction, and 
overexpression of LKB1 causes p21WAF1/CIP1-induced gr-
owth arrest in cells with undetectable or low levels of endog-
enous LKB1.
11) In contrast to kinase activity, although Brg1-
associated growth arrest also requires LKB1 kinase activity, 
wild-type LKB1 and the kinase-deficient form LKB1-SL26 
both stimulate Brg1 ATPase.
25) This suggests that some regu-
latory functions of LKB1 may not require its kinase activity.
19) 
As is well known, LKB1 has an autophosphorylation activity 
to increased its kinase activity. Our data showed that Ang II 
induces LKB1 expression in VSMCs and that LKB1 expres-
sion increased after vascular injury. However, increased LKB1 
expression was not correlated with LKB1 kinase activity in 
the balloon-injured carotid arteries. These findings suggest 
Sham
Sham
Injury
Injury
Injury+Ang II
Injury+Ang II
Fig. 2. A, B and C: representative microphotographs of H&E staining in balloon-injured carotid artery at day 14 (200×, n=3/each group). A: 
sham operation. B: balloon-injured carotid artery. C: balloon-injured and Ang II infusion via a miniosmotic pump. A neointima was found 2 
weeks after carotid artery balloon injury. A marked neointima was found after balloon injury (*). D, E and F: representative microphotographs 
of LKB1 immunohistochemistry stain in balloon-injured carotid artery at day 14 (400×, n=3/each group). D: sham operation. E: balloon-injured 
carotid artery. F: balloon-injured and Ang II infusion via a miniosmotic pump. LKB1 expression was increased after carotid artery balloon injury. 
LKB1 expression was more greatly increased by Ang II after carotid artery balloon injury. Expression of LKB1 was graded according to the follow-
ing scale by two investigators blinded to the experimental conditions: negative (0), mild staining (1), moderate staining (2), and intense staining 
(3). I: representative western blot of the LKB1 in balloon-injured carotid artery at day 14 (n=3/each group). The carotid artery lysates containing 
an equal amount of protein from each condition were analyzed by Western blotting for LKB1 using specific antibodies. Western blot of LKB1 ex-
pression was similar to immunohistochemistry. LKB1 expression increased after carotid artery balloon injury. LKB1 expression was more greatly 
increased by Ang II after carotid artery balloon injury.
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that some regulatory functions of increased LKB1 in VSMC 
and neointima do not require kinase activity. There might be 
some mechanisms which interfere with increased LKB1 ex-
pression and kinase activity. 
There are several limitations to this study. First, we failed 
to transfect LKB1 to evaluate the direct effect of LKB1, with 
or without AII stimulation, on proliferation of VSMC in vitro 
and in vivo. It is unclear whether Ang II-induced LKB1 plays 
a positive or negative regulatory role in SMC proliferation. 
Second, we only checked LKB1 activity after vascular injury 
without exogenous Ang II infusion. Although endogenous 
Ang II increased after vascular injury, the mechanisms of the 
interaction between Ang II, increased LKB1 expression and 
decreased LKB1 kinase activity is still elusive. Since LKB1 ac-
tivity is dependent on post-translational modification, such 
as phosphorylation or acetylation, further study is needed to el-
ucidate the molecular mechanisms of how Ang II increases 
LKB1 expression and decreases activity in VSMC and neointi-
ma formation.
In conclusion, LKB1 was expressed in the VSMCs and 
neointima. Ang II increases tumor suppressor serine/threo-
nine kinase LKB1 expression in the VSMCs and neointima of 
the rat carotid artery injury model. These findings were not 
kinase dependant. The LKB1 might be one of the regulators of 
VSMC proliferation and neointima formation.
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